Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that the Monitoring Board for the Phase IIa trial of drug candidate QGC001 – a group of independent experts tasked with regularly reviewing it and, if necessary, the tolerance data from the trial – met for the first time on 29 September 2015.
After analysing all the clinical and biological monitoring data, the Board recommended that the trial continues as planned.
Olivier Madonna, Chief Medical Officer of Quantum Genomics, says :
“These positive results for patient tolerance of our drug candidate support our intention to continue clinical development as planned, as a treatment for high blood pressure and heart failure.”
As a reminder, this clinical trial is a randomised double-blind study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aims to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.
On 8 September 2015, Quantum Genomics announced it had now recruited more than 50% of the patients, four months ahead of schedule, and had fully completed the trial for over a third of the patients (read the press release of 8 September 2015).
In addition to its presence at the European Large & Midcap Event, to be held in Palais Brongniart in Paris on October 7 & 8, 2015, Quantum Genomics will be participating at the Emerging Leaders in European Healthcare conference, to be held on October 22 in New York. Furthermore, the FINANCIAL results for the first half of 2015 will be released on October 15 (after trading).
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance et communication
01 53 67 36 73
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (isin code FR0011648971, Ticker ALQGC).